Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia

Expert Opinion on Biological Therapy

Volumn 10, Issue 8, 2010, Pages 1241-1250

  Penna, Fabio ^a   Minero, Valerio G ^a   Costamagna, Domiziana ^a   Bonelli, Gabriella ^a   Baccino, Francesco M ^a   Costelli, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Anorexia; Cachexia; Emerging drugs; Proinflammatory cytokines

Indexed keywords

3,3 BIS(3,4 DIMETHOXYPHENIL)ARCYLONITRILE; ACRYLONITRILE; ADALIMUMAB; ALD 518; ANTIINFLAMMATORY AGENT; ATRACTYLENOLIDE; AVR 118; CERTOLIZUMAB PEGOL; CYTOKINE ANTIBODY; DOCETAXEL; ETANERCEPT; GAMMA INTERFERON; GEMCITABINE; HYDROXAMIC ACID; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MYOSTATIN; ONERCEPT; PENTOXIFYLLINE; PLACEBO; PLANT MEDICINAL PRODUCT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; AUTACOID; CYTOKINE;

ANOREXIA; CACHEXIA; CANCER MORTALITY; CATABOLISM; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HOMEOSTASIS; HUMAN; LUNG NON SMALL CELL CANCER; MORBIDITY; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PHYSICAL ACTIVITY; PROTEIN DEGRADATION; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SKELETAL MUSCLE; TUMOR CELL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HUMORAL IMMUNITY; IMMUNOLOGY; NEOPLASM; TREATMENT OUTCOME;

ANOREXIA; ANTI-INFLAMMATORY AGENTS; CACHEXIA; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNITY, HUMORAL; INFLAMMATION MEDIATORS; NEOPLASMS; TREATMENT OUTCOME;

EID: 77954688185     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.503773     Document Type: Review

References (103)

1. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008;11:400-407
2. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008;27:793-799
3. Muscaritoli M, Anker SD, Argiles, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". J Clin Nutr 2010;29:154-159
4. Loberg RD, Bradley DA, Tomlins SA, et al. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007;57:225-241
5. Muscaritoli M, Bossola M, Aversa Z, et al. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006;42:31-41
6. Costelli P, Baccino FM. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 2003;6:407-412
7. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 2007;13:1356-1361
8. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708
9. Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 2002;290:1-10
10. Du J, Hu Z, Mitch WE. Cellular signals activating muscle proteolysis in chronic kidney disease: a two-stage process. Int J Biochem Cell Biol 2005;37:2147-2155
11. Masiero E, Agatea L, Mammucari C, et al. Autophagy is required to maintain muscle mass. Cell Metab 2009;10:507-515
12. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003;11:60-62
13. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003;4:686-694
14. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404:661-671
15. Perboni S, Inui A. Anorexia in cancer: role of feeding-regulatory peptides. Philos Trans R Soc Lond B Biol Sci 2006;361:1281-1289
16. Lelbach A, Muzes G, Feher J. Current perspectives of catabolic mediators of cancer cachexia. Med Sci Monit 2007;13:RA168-173
17. Mantovani A, Allavena P, Sica A, et al. Cancer associated inflammation. Nature 2008;454:436-444
18. Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009;3:263-268
19. Costelli P, Carbo N, Tessitore L, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993;92:2783-2789
20. Llovera M, Garcia-Martinez C, Lopez-Soriano J, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998;142:183-189
21. Argiles JM, Lopez-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998;1:245-251
22. Attard-Montalto SP, Hadley J, Kingston JE, et al. Ongoing assessment of nutritional status in children with malignant disease. Pediatr Hematol Oncol 1998;15:393-403
23. Dworzak F, Ferrari P, Gavazzi C, et al. Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover. Cancer 1998;82:42-48
24. Bossola M, Muscaritoli M, Bellantone R, et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest 2000;30:1107-1112
25. Guasconi V, Puri PL. Epigenetic drugs in the treatment of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 2008;11:233-241
26. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med 2003;9:344-350
27. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412
28. Latres E, Amini AR, Amini AA, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005;280:2737-2744
29. Penna F, Bonetto A, Muscaritoli M, et al. Muscle atrophy in experimental cancer cachexia: Is the IGF-1 signaling pathway involved? Int J Cancer [Epub ahead of print; 28 December 2009, doi:10.1002/ijc.25146]
30. Liu CM, Yang Z, Liu CW, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther 2007;14:945-952
31. Costelli P, Muscaritoli M, Bonetto A, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008;38:531-538
32. Bonetto A, Penna F, Minero VG, et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 2009;9:608-616
33. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-1488
34. McFarlane C, Plummer E, Thomas M, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006;209:501-514
35. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-421
36. Bogdanovich S, McNally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 2008;37:308-316
37. Akpan I, Goncalves MD, Dhir R, et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 2009;33:1265-1273
38. Benny Klimek ME, Aydogdu T, Link MJ, et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010;391:1548-1554
39. Baracos VE. Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies. Cancer 2001;92:1669-1677
40. Saini A, Al-Shanti N, Stewart CE. Waste management - cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 2006;17:475-486
41. Argiles JM, Lopez-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008;13:73-78
42. Baracos VE, Mazurak VC, Ma DW. n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev 2004;17:177-192
43. Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003;52:1479-1486
44. Mantovani G, Madeddu C. Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia. Curr Opin Support Palliat Care 2008;2:275-281
45. Hunter DC, Weintraub M, Blackburn GL, Bistrian BR. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg 1989;76:149-153
46. May PE, Barber A, D'Olimpio JT, et al. Reversal of cancer-related wasting using oral supplementation with a combination of b-hydroxy-b-methylbutyrate, arginine and glutamine. Am J Surg 2002;183:471-479
47. Foster AC, Chen C. Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia. Curr Top Med Chem 2007;7:1131-1136
48. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebocontrolled trial. J Clin Endocrinol Metab 2004;89:2832-2836
49. Das BK, Mishra S, Padhi PK, et al. Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults. Trop Med Int Health 2003;8:680-684
50. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997;155:1665-1669
51. Hoechst AG. Use of pentoxifyllin in treating inflammatory diseases. EP0351885; 1993
52. Hoechst Roussel Pharma; Univ Virginia (Hoechst-Roussel Pharmaceuticals, Inc., The University of Virginia Alumni Patents Foundation). Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines. W08804928; 1997
53. Bryson Nathan. Combination for treatment of diabetes mellitus. WO2008151415; 2008
54. Costelli P, Bossola M, Muscaritoli M, et al. Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca2+-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine 2002;19:1-5
55. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856-2859
56. Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998;25:53-57
57. Celgene Corp. Process for the preparation of thalidomide. W09501348; 1995
58. Tobinik Edward L. Cytokine antagonists for the treatment of sensorineural hearing loss. US2001004456; 2001
59. Unicamp, Univ Fed Do Rio de Janeiro UFR, Univ Estadual Paulista Julio D, Dos Santos Jean Leandro, Chung Man Chin, Moreira Lima Lidia, Ferreira Costa Fernando, Lanaro Carolina. Use of phthalimide and/or sulphonamide derivatives in the treatment of diseases which require reducing the TNF-alpha levels and an exogenous source of nitric oxide, phthalimide derivatives, sulphonamide derivatives, and a method for obtaining a sulphonam. WO2009073940; 2009
60. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 1999;10:857-859
61. Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003;17:677-682
62. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005;54:540-545
63. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-1350
64. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733
65. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-736
66. Xue CB, Voss ME, Nelson DJ, et al. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem 2001;44:2636-2660
67. Murumkar PR, DasGupta S, Chandani SR, et al. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin Ther Patent 2010;20:31-57
68. American Cyanamid Co. Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors. WO0044749; 2003
69. Ohta S, Harigai M, Tanaka M, et al. Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J Rheumatol 2001;28:1756-1763
70. Thabet MM, Huizinga TW. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 2006;7:1014-1019
71. Sagami Chem Res, Tsuji Tomoko, Yamaguchi Kohji, et al. Interleukin-6 production inhibitor. WO9735581; 1997
72. Toray Industries. Interleukin-6 production inhibitors. US6579860; 2003
73. Zhang Junping. New use of 3,7,3'4'-substituted flavone. CN1526388; 2004
74. Celgene Co. Immunotherapeutic agents and their use in the reduction of cytokine levels. WO9806692; 2003
75. Hy Biopharma, Inc. Polycyclic dianthraquinones as inhibitors of inflammatory cytokines. US2010048728; 2010
76. Bork PM, Bacher S, Schmitz ML, et al. Hypericin as a non-antioxidant inhibitor of NF-kappaB. Planta Med 1999;65:297-300
77. Liu Y, Jia Z, Dong L, et al. A randomized pilot study of atractylenolide I on gastric cancer cachexia patients. Evid Based Complement Alternat Med 2008;5:337-344
78. Chasen MR, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid AVR118 in the management of cancer related anorexia/cachexia, 5th Cachexia Conference; 5 - 8 December 2009; Barcelona:abstracts p.54
79. Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target. Mol Biotechnol 2005;31:239-244
80. Tact Ip, LLC. Use and methods of use of etanercept and other TNF binding biologics to improve human cognitive function. US2006009450; 2006
81. Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Ann Rheum Dis 2005;64:1137-1140
82. Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463-1472
83. Costelli P, Llovera M, Carbo N, et al. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett 1995;95:33-38
84. Jatoi A, Dakhil SR, Nguyen PL, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007;110:1396-1403
85. Wiedenmann B, Malfertheiner P, Friess H, et al. A multicenter, Phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25
86. Kishimoto Chuzo, Chugai Pharmaceutical Co. Ltd. Therapeutic agent for disease due to IL-6 production. JP8169846; 1996
87. Clarke S, Gebbie C, Sweeney C, et al. 5th Cachexia Conference; 5 - 8 December 2009; Barcelona:abstracts p.53
88. Kishimoto Chuzo; Chugai Pharmaceutical Co. Ltd. Therapeutic agent of disease caused by IL-6 production. US2007036785; 2008
89. Kishimoto Chuzo; Chugai Pharmaceutical Co. Ltd. Method for inhibiting muscle protein proteolysis with antibodies to Interleukin-6 receptor. US6261560; 2001
90. Enomoto A, Rho MC, Fukami A, et al. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun 2004;323:1096-1102
91. Orchid Res Laboratory Ltd. Novel heterocycles. US2007167413; 2007
92. Otsuka America Pharmaceutical. Treatment of cachexia and inhibition of IL-6 activity. W09408574; 1994
93. Otsuka Pharma Co. Ltd. Method to mitigate or eliminate weight loss. US5453444; 1995
94. Erba Carlo SPA. Novel therapy for disease related to tumor necrosis factor (TNF). EP0486809; 1992
95. Strassmann G, Fong M, Freter CE, et al. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 1993;92:2152-2159
96. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-675
97. Ikeda U, Shimada K. Statins and monocytes. Lancet 1999;353:2070
98. Dichtl W, Dulak J, Frick M, et al. HMGCoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:58-63
99. Garjani A, Andalib S, Ziaee M, Maleki-Dizaji N. Biphasic effects of atorvastatin on inflammation. Pak J Pharm Sci 2008;21:125-130
100. Imp Innovations Ltd. Treatment of cachexia with statins. EP1973542; 2008
101. Muscaritoli M, Costelli P, Bossola M, et al. Effects of simvastatin administration in an experimental model of cancer cachexia. Nutrition 2003;19:936-939
102. Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care 2008;2:267-274
103. Durham WJ, Dillon EL, Sheffield-Moore M. Inflammatory burden and amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care 2009;12:72-77